Published on 02/12/2025

SUS in Continuous Manufacturing: Dynamic E&L Considerations

The emergence of single-use systems (SUS) in continuous manufacturing has drawn significant attention due to its potential to streamline processes and reduce contamination risks. However, with these advancements come concerns regarding extractables and leachables (E&L) that can impact product safety and efficacy. This tutorial will provide a comprehensive step-by-step guide to addressing E&L considerations in the context of continuous manufacturing, focusing on filters, container closure integrity, and regulatory compliance.

Understanding Extractables and Leachables (E&L)

Extractables and leachables are impurities that may migrate from drug packaging and delivery systems into pharmaceutical products, posing potential risks to patients. Extractables are substances released when a material is exposed to a solvent under specific conditions, typically in a laboratory setting. In contrast, leachables are components that migrate into the product under normal storage and usage conditions.

Applying E&L risk assessment principles is critical to ensuring that the use of SUS does not introduce unacceptable levels of contaminants. The E&L assessment process consists of several key components:

• Material Characterization: Identify the materials used in the SUS, including filters, bags, and tubing.
• Analytical Evaluation Threshold (AET): Establish a threshold below which E&L contaminants are considered insignificant.
• Risk Assessment: Evaluate the potential risks associated with the identified E&L components based on their toxicological profiles and exposure routes.

Establishing Analytical Evaluation Threshold (AET)

The Analytical Evaluation Threshold (AET) is a crucial concept in E&L assessments, which aids in determining the significance of extractables and leachables identified during testing. The AET allows manufacturers to focus on potentially harmful substances while disregarding those below a defined threshold. This not only ensures a more efficient evaluation process but also satisfies regulatory expectations.

To calculate the AET, follow these steps:

1. Pharmacological Risk Assessment: Identify the toxicological endpoints relevant to the use of the product, considering the patient population.
2. Determine Safety Factors: Apply safety factors based on the route of exposure and duration of exposure to refine the thresholds.
3. Establish AET Values: Use the calculated values to define the AET based on the highest safe daily intake of relevant substances.

Dose-Based Threshold (DBT) Calculation

The Dose-Based Threshold (DBT) adds an additional layer of evaluation to the E&L assessment process. While the AET defines acceptable levels of contaminants solely based on analytical results, the DBT incorporates exposure consideration into the safety assessment. The DBT calculation takes into account the mass or volume of the drug product and helps ensure that any leachables or extractables do not exceed safety limits when considering a specific dosage.

To conduct a DBT calculation:

1. Determine Maximum Daily Dose: Identify the maximum concentration of the drug administered to patients daily.
2. Calculate Acceptable Exposure: Calculate the acceptable exposure levels for identified leachables based on their toxicological data.
3. Finalize DBT: Iterate across the relevant leachables to ensure that the detected levels do not exceed established safety thresholds.

Container Closure Integrity (CCI) Testing

The evaluation of Container Closure Integrity (CCI) is vital in ensuring that the product remains protected from external contaminants throughout its shelf life. CCI testing involves evaluating the ability of the packaging system to provide a barrier to contamination. This is particularly crucial when using SUS, given the variations in materials and processes involved in their manufacture.

The following testing methods are commonly used:

• Vacuum Decay Method: Measures leakage by creating a vacuum and monitoring pressure changes over time.
• Helium Leak Testing: Utilizes helium gas to detect leaks through packaging materials.
• Dye Penetration Method: Assesses packaging integrity by observing the migration of dye into the product.

Regulatory Guidelines and Compliance

Compliance with regulatory expectations is essential when implementing E&L practices in single-use systems within continuous manufacturing. The FDA provides comprehensive guidelines detailing the expectations for pharmaceutical manufacturing processes to ensure that patient safety is prioritized.

Similarly, the EMA and MHRA have established their own robust frameworks for evaluating E&L, specifically detailed in the EU GMP Annex 1. Compliance with these guidelines not only mitigates risk but enhances the defensibility of E&L assessment but also contributes to the overall quality management system (QMS) of the organization.

Practical Considerations for E&L in Continuous Manufacturing

Implementing E&L assessments in continuous manufacturing necessitates an understanding of the unique challenges presented by single-use systems. The following strategies can enhance your E&L risk assessment capabilities:

• Cross-function Collaboration: Involve cross-functional teams from R&D, quality assurance, and regulatory affairs early in the product development cycle to harmonize process evaluations.
• Pre-qualification of Materials: Conduct thorough pre-qualification of single-use materials and components to ensure they meet established E&L requirements.
• Regular Review of Suppliers: Maintain an ongoing assessment of suppliers’ capabilities in manufacturing and supplying single-use systems that comply with E&L standards.

Case Studies: Real-world Applications of E&L in Continuous Manufacturing

Exploring diverse case studies can illuminate the importance of robust E&L assessment strategies. Several pharmaceutical manufacturers have successfully integrated E&L principles into their operations, yielding positive outcomes:

• Case Study 1: A large biotech manufacturer implemented a multi-phase approach to E&L assessment, resulting in a reduction of leachables by over 50% while maintaining product integrity.
• Case Study 2: Using an analytical method that combined AET and DBT calculations, a generic manufacturer enhanced product safety, achieving successful regulatory clearance with zero adverse findings.
• Case Study 3: After a CCI testing initiative led by a global pharmaceutical company, packaging integrity saw significant improvements, which streamlined the product release process.

Conclusion

The dynamic landscape of continuous manufacturing calls for a vigilant approach to managing E&L risks associated with single-use systems. By employing precise methodologies, including AET and DBT calculations, along with stringent CCI testing, pharmaceutical professionals can navigate regulatory landscapes while ensuring patient safety and product integrity. Building frameworks for collaboration, ongoing supplier assessments, and integrating case studies are pivotal in optimizing E&L commodities in drug manufacturing.

As continuous manufacturing becomes increasingly prevalent, staying abreast of regulatory guidelines from various authorities, including the ICH and the PQRI guideline, is crucial for maintaining compliance and ensuring successful product outcomes.